文献速递妇科肿瘤

铂敏感复发性卵巢癌腹腔热灌注化疗:生存评估随机试验(HORSE;MITO-18)

Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).
PubMed 文献 · J Clin Oncol · 2024-11-21

这项多中心随机III期研究纳入167例铂敏感复发性上皮性卵巢癌患者,在残余肿瘤≤0.25 cm时随机分为二次肿瘤细胞减灭术(SCS)联合腹腔热灌注化疗(HIPEC)组82例与单纯SCS组85例。中位随访83个月,两组中位无进展生存期(PFS)分别为25个月与23个月,5年复发后生存率分别为75.9%与61.6%,术后不良事件发生率相似。结论认为在完全或近完全初次SCS基础上加用HIPEC未带来PFS获益。

要点

  • 铂敏感复发性卵巢癌SCS后加HIPEC未改善PFS:联合组25个月 vs 单纯手术组23个月。
  • 5年复发后生存率联合组75.9% vs 单纯手术组61.6%。
  • 两组术后任何级别不良事件发生率相似。

核心结论

  • 在铂敏感腹膜复发性卵巢癌患者中,完全或近完全初次二次肿瘤细胞减灭术后加用HIPEC未带来无进展生存获益。

研究设计与样本

  • 多中心随机III期研究,在手术时对残余肿瘤≤0.25 cm者随机分组。
  • 共167例患者随机分组,SCS联合HIPEC组82例,单纯SCS组85例。
  • 实验组在手术结束时行HIPEC:顺铂75 mg/m2,41.5°C,60分钟。
  • 两组术后均接受铂类化疗;主要终点为PFS,次要终点为安全性和复发后生存(PRS)。

主要发现

  • 中位随访83个月(IQR 64-102)。
  • 中位PFS:单纯手术组23个月(95% CI 17-29)vs SCS联合HIPEC组25个月(95% CI 18-32)。
  • 5年PRS概率:单纯SCS组61.6%(95% CI 50.8-72.4)vs SCS联合HIPEC组75.9%(95% CI 66.5-85.3)。
  • 两组术后任何级别不良事件发生率相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to secondary cytoreductive surgery (SCS) without neoadjuvant chemotherapy has a benefit on progression-free survival (PFS), as opposed to SCS alone in patients with platinum-sensitive recurrent epithelial ovarian cancer (platinum-free interval, >6 months). METHODS: This was a multicenter randomized phase III study. Random assignment was performed at the time of surgery in cases with residual tumor ≤0.25 cm. HIPEC with cisplatin (CDDP) 75 mg/m2 for 60 minutes at 41.5°C was administered at the end of surgery in the experimental arm. Both groups received postoperative platinum-based chemotherapy. The primary end point was PFS. The safety profile and postrecurrence survival (PRS) were the secondary end points. RESULTS: A total of 167 patients underwent random assignment, 82 patients to SCS plus HIPEC (experimental arm) and 85 to SCS alone (control arm). The median follow-up was 83 months (IQR, 64-102). The median PFS was 23 months (95% CI, 17 to 29) in the group that underwent surgery alone and 25 months (95% CI, 18 to 32) in the group that underwent cytoreductive surgery with HIPEC. The probability of PRS at 5 years was 61.6% (95% CI, 50.8 to 72.4) in the SCS group and 75.9% (95% CI, 66.5 to 85.3) in the SCS plus HIPEC group. The incidence of postoperative adverse events of any grade was similar between the two groups. CONCLUSION: The addition of HIPEC to complete or nearly complete primary SCS did not confer a benefit in terms of PFS in patients with platinum-sensitive peritoneal recurrence.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fagotti A, Costantini B, Fanfani F, et al. Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18). J Clin Oncol. 2024. PMID: 39571127. doi:10.1200/JCO.24.00686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。